Duopharma is First in Malaysia to Receive Halal Certification for Oncology Product
Highlights: In December 2022, Duopharma Biotech Bhd made history by becoming the first pharmaceutical company to receive halal certification for an oncology product. The product is currently used as an adjuvant treatment for postmenopausal women with early breast cancer, as well as a first-line treatment for postmenopausal women with advanced breast cancer. The halal-certified oncology product is produced at Duopharma Biotech’s Highly Potent Active Pharmaceutical Ingredients (HAPI) facility in Glenmarie, Shah Alam, and is supplied to both government and private healthcare hospitals in Malaysia. The product has also been approved for export to Brunei and Singapore, signaling a growing demand for halal-certified pharmaceuticals in the region. Duopharma Biotech’s achievement represents a major milestone for the halal pharmaceutical industry and underscores the company’s commitment to providing safe and effective halal-certified products to patients.
Link to Original Article